Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rivaroxaban plus ticagrelor in atrial fibrillation patients undergoing PCI
ChiCTR1900023673Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban and ticagrelor in Atrial fibrillation (AFib) and coronary arteriosclerosis, sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoints: Clinical bleeding events and Composite major cardiovascular adverse events. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
rivaroxabanticagrelor
03
Conditions
Atrial fibrillation (AFib)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1900023673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023673.